AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00989950
Drug: Daytrana
RxNorm normalized name: Daytrana
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daytrana 10-30 mg worn once daily for 10 hr wear
Trial: NCT00989950
Drug: Daytrana
RxNorm normalized name: Daytrana
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daytrana 10-30 mg worn once daily for 11 hr
Trial: NCT00989950
Drug: Daytrana
RxNorm normalized name: Daytrana
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daytrana 10-30 mg worn once daily for 12 hrs
Trial: NCT00482014
Drug: pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Phase 1 - 500 milligram/meter squared (mg/m²), administered intravenously, every 21 days for 3 cycles~Phase 2 - 500 mg/m², administered intravenously, every 21 days for 3 cycles~Consolidation Therapy - 500 mg/m² pemetrexed, administered intravenously, every 21 days for 3 cycles beginning 3 weeks after completion of chemoradiation therapy for each phase
Trial: NCT00482014
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phase 1 - 30 mg/m² and 75 mg/m², administered intravenously, Days 1, 8, 22, 29 and 43~Phase 2 - 75 mg/m², administered intravenously, every 21 days for 3 cycles
Trial: NCT00482014
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Phase 1 - dosed at area under the curve (AUC) 2 milligram/milliliter\*minute (mg/mL\*min), administered intravenously, Days 1, 8, 22, 29 and 43~Phase 2 - dosed at AUC 5 mg/mL\*min, administered intravenously, every 21 days for 3 cycles
Trial: NCT00313937
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00479154
Drug: Botulinum Toxin A
RxNorm normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Maximum dose of 90 units/leg was injected.
Trial: NCT03574051
Drug: Probiotic
RxNorm normalized name: PROBIOTIC
DrugBank: Lactobacillus acidophilus (DB15823)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evaluate probiotics for preventing adverse effects of hypothyroidism and improvement of side effects caused by 131I treatment
Trial: NCT03612154
Drug: Lorlatinib
RxNorm normalized name: LORLATINIB
DrugBank: Lorlatinib (DB12130)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects will be treated with lorlatinib 100mg PO daily. A cycle will be defined as 28-days for the convenience of analysis.
Trial: NCT01438060
Drug: Aripiprazole (BMS-337039)
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Acute Phase: Oral, Tablets (1 and 5 mg), Week 1-2: 2 mg, Week 3-4: 2 - 5 mg, Week 5-6: 2 - 10 mg, Weeks 7-10: 2 - 15 mg, Once daily, 10 weeks~Extension Phase: Oral, Tablets (1 and 5 mg), Week 11: 2 mg, Weeks 12-13: 2 - 5 mg, Weeks 14-15: 2 - 10 mg, Weeks 16-140: 2 - 15 mg, Once daily, 130 weeks
Trial: NCT02329353
Drug: Lactobacillus brevis CD2 Lozenges
RxNorm normalized name: lactobacillus brevis CD2
DrugBank: Lactobacillus brevis (DB18532)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each lozenge contains not less than 1 billion Colony forming unit of Lactobacillus brevis CD2
Trial: NCT01099072
Drug: Methylphenidate+placebo
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: methylphenidate at a dose of 20-30 mg/day depending on weight (20 mg/day for \<30 Kg and 30 mg/day for \>30 Kg)+ Placebo
Trial: NCT01099072
Drug: methylphenidate+carnitine
RxNorm normalized name: carnitine
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: methylphenidate at a dose of 20-30 mg/day depending on weight (20 mg/day for \<30 Kg and 30 mg/day for \>30 Kg)+ Carnitine 500-1500 mg/day (depending on weight )
Trial: NCT01461174
Drug: Modafinil
RxNorm normalized name: Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg tablet, single dose
Trial: NCT02518139
Drug: TD-4208
RxNorm normalized name: triamcinolone diacetate Injectable Suspension [TDS Forte]
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects receiving TD-4208 are blinded to one of two doses of 4208.
Trial: NCT02518139
Drug: Tiotropium
RxNorm normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There is not a placebo, there is an active comparator (Tiotropium) arm.
Trial: NCT01461174
Drug: Donepezil
RxNorm normalized name: Donepezil
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Donepezil or placebo, 5 mg tablet one per day, 15 days
Trial: NCT01461174
Drug: Memantine
RxNorm normalized name: Memantine
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Memantine or placebo, 10 mg tablet one per day, 15 days
Trial: NCT00234312
Drug: escitalopram and sertraline
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02977169
Drug: Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin/ carboplatin + vinorelbine regimen for squamous cell lung carcinoma Cisplatin/carboplatin + pemetrexed regimen for lung adenocarcinoma
Trial: NCT02338440
Drug: lipoprostaglandin E1
RxNorm normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Blood sampling before administration (baseline), between 1 hour to 72 hours from administration (plateau 1), 72 hours after engraftment (plateau 2), when the clinician determine to do blood sampling because of change of kidney/liver function change (optional 1), 72 hours from the change of lipoprostaglandin E1 concentration change (optional 2)
Trial: NCT04669782
Drug: Teriparatide
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Teriparatide will be administered as standard of care
Trial: NCT01532414
Drug: Androxal
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral, capsules, taken one time daily, for 3 months
Trial: NCT00081484
Drug: epoetin alfa or beta
RxNorm normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: iv or sc, as prescribed
Trial: NCT00081484
Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
DrugBank: Methoxy polyethylene glycol-epoetin beta (DB09107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30, 50 or 90 micrograms iv or sc (starting dose) every 2 weeks
Trial: NCT00482612
Drug: Esmirtazapine
RxNorm normalized name: Esmirtazapine
DrugBank: Esmirtazapine (DB06678)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmirtazapine maleate was provided as tablets for oral use containing either 1.5, 3.0, or 4.5 mg of active compound. In addition, tablets contain the following excipients: hydroxypropyl cellulose, maize starch (United States Pharmacopeia \[USP\] name: corn starch), magnesium stearate, and lactose monohydrate. Tablets were administered orally once daily about 30 minutes prior to bedtime.
Trial: NCT01311947
Drug: Peginterferon alfa-2a
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peginterferon alfa-2a at 180 ug weekly for 24 weeks
Trial: NCT00112905
Drug: sorafenib tosylate
RxNorm normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00264134
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00264134
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00264134
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02252016
Drug: Grazoprevir + Elbasvir
RxNorm normalized name: elbasvir / grazoprevir
DrugBank: Elbasvir (DB11574)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FDC tablet containing grazoprevir 100 mg + elbasvir 50 mg taken once daily by mouth.
Trial: NCT02304198
Drug: Udenafil
RxNorm normalized name: udenafil
DrugBank: Udenafil (DB06267)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Udenafil 50mg tablet
Trial: NCT00509990
Drug: Pimecrolimus
RxNorm normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pimecrolimus cream 1 %
Trial: NCT01003938
Drug: Topotecan
RxNorm normalized name: Topotecan
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01003938
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02324452
Drug: Fluoropyrimidine (capecitabine or 5-fluorouracil)
RxNorm normalized name: 5-Fluoropyrimidine-2,4-dione
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patient that are a heterozygous carrier of a DPYD variant will receive a reduced dosage of capecitabine or 5-fluorouracil (25-50% reduction, depending on which SNP is identified). The dose will be titrated in subsequent cycles, to achieve maximal safe exposure. Patients that are wild type (not carrying any of the for DPYD variants) will receive a normal (full) dose.
Trial: NCT02372006
Drug: afatinib
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00880815
Drug: Bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00880815
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01452347
Drug: warfarin 1mg
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: comparator warfarin
Trial: NCT01452347
Drug: dabigatran etexilate intermediate dose
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: active treatment (medium)
Trial: NCT01452347
Drug: dabigatran etexilate low dose
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: active treatment (low)
Trial: NCT01452347
Drug: warfarin 5mg
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: comparator warfarin
Trial: NCT00880815
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV and PO
Trial: NCT03118297
Drug: Ulipristal Acetate
RxNorm normalized name: Ulipristal Acetate
DrugBank: Ulipristal (DB08867)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Women who have bothersome bleeding with the etonogestrel implant will be randomized to receive ulipristal acetate versus placebo daily for 7 days.
Trial: NCT00540579
Drug: Pomalidomide
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Phase 1: Subjects will be enrolled in dose-escalating cohorts to be treated with CC-4047 on days 1-21 Phase II: Subjects will be enrolled to receive oral CC-4047 at the MTD days 1 - 21
Trial: NCT00540579
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m2 IV on days 1, 8, and 15 of 28 day cycle
Trial: NCT02268435
Drug: dovitinib plus imatinib
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dovitinib once daily on a 5 days on/2 days off dosing schedule, and imatinib once daily on a continuous dosing schedule
Trial: NCT01394445
Drug: Physostigmine
RxNorm normalized name: PHYSOSTIGMINE
DrugBank: Physostigmine (DB00981)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: continuous intravenous infusion per syringe pump (13 vials of 2 mg/5 ml --\> 26 mg/65 ml; 1 ml = 0.4 mg Physostigmine) at rate of 1 mg/h (2.5ml/h) for 24 hours
Trial: NCT01452347
Drug: dabigatran etexilate high dose
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: active treatment (high)
Trial: NCT01452347
Drug: warfarin 3mg
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: comparator warfarin
Trial: NCT00109954
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01956812
Drug: IMMU-107
RxNorm normalized name: IMMU-114
DrugBank: IMMU-114 (DB18458)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm A: gemcitabine 200 mg/m2 administered weekly x 4 and IMMU-107 administered weekly x 3 for multiple cycles
Trial: NCT01956812
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine, 200 mg/m2, given weekly x 4 in both arms
Trial: NCT00253305
Drug: Organogel of naftifine, 2%
DrugBank: Naftifine (DB00735)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00253305
Drug: Organogel of terbinafine, 2%
DrugBank: Terbinafine (DB00857)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00253305
Drug: Organogel of terbinafine, 6%
DrugBank: Terbinafine (DB00857)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00170430
Drug: Fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00170430
Drug: Metronizadole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01418001
Drug: Pazopanib 400 mg QD - Gemcitabine and Docetaxel in Combination
RxNorm normalized name: PAZOPanib 400 MG
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients who meet the eligibility criteria above will be treated with the combination therapy of Gemcitabine, Docetaxel, and Pazopanib for two cycles and subsequently re-evaluated for treatment effect. If no progression of the tumor is seen, patients will continue with two more cycles of treatment (total four cycles). Those patients who have progression of disease will proceed directly to surgical resection.~Following completion of neoadjuvant treatment, all patients will have definitive surgical resection. Following recovery from surgery, patients will proceed with adjuvant radiation therapy. Patients will then be followed for 2 years or until January 1st 2015, whichever comes first .
Trial: NCT00168831
Drug: Tiotropium Inhalation Solution
RxNorm normalized name: tiotropium Inhalation Powder
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03097198
Drug: Tropicamide Eye Drops
DrugBank: Tropicamide (DB00809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Instill one drop in both eyes every night before bed.
Trial: NCT00582205
Drug: Paclitaxel, Cisplatin IP
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paclitaxel 135 mg/m2 IV (3-hr infusion) on Day 1, Cisplatin 50 mg/m2 IP on Days 1 and 8, Repeat every 3 weeks for 6 cycles
Trial: NCT00672373
Drug: Extract of Ginkgo Biloba (EGb-761 capsules)
RxNorm normalized name: Ginkgo biloba extract
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGb-761 240mg/d, 1 capsule(80mg) tid,po,12 weeks; Each capsule contains 19.6mg flavonol glycosides and 4.8mg terpene lactones.
Trial: NCT00326872
Drug: Cediranib Maleate
RxNorm normalized name: maleate
DrugBank: Cediranib (DB04849)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03717701
Drug: metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will take metformin single dose of 1000 mg orally once a day
Trial: NCT03717701
Drug: esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will take esomeprazole single dose of 40 mg orally once a day
Trial: NCT01044966
Drug: ITV DepoCyt + Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intrathecal liposomal Ara-C dosing will begin at 50 mg ITV every 2-4 weeks, and de-escalated based on toxicity obtained from the Phase I portion of the trial. Metronomic dosing of temozolomide will be given at 75 mg/m2 for 21 days (continuous oral dosing), followed by 7 days off in a 28 day cycle as a once daily dosing regimen.
Trial: NCT01425840
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg of the following formulations: Liposome-encapsulated 2,5% and 5% lidocaine gel, liposome placebo gel and 2.5% lidocaine and 2.5% prilocaine cream were applied once during 5 minutes.
Trial: NCT01371617
Drug: IPI-926
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single Arm study of oral IPI-926 at 160 mg, 130 mg or 110 mg daily, until progressive disease or intolerability to study treatments or withdrawal of ICF
Trial: NCT00991796
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel concentrate for solution for infusion. once every 3 weeks for a maximum of 6 cycles. 175 mg/m2
Trial: NCT00230516
Drug: Nexium
RxNorm normalized name: Nexium
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00230516
Drug: Prevacid
RxNorm normalized name: Prevacid
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03742349
Drug: capmatinib
RxNorm normalized name: CAPMATINIB
DrugBank: Capmatinib (DB11791)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablet
Trial: NCT02128126
Drug: ISA101/ISA101b
DrugBank: ISA101b (DB18694)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four dose levels ISA101/ISA101b
Trial: NCT01833130
Drug: Normal saline (placebo)
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Normal saline) injected into specified head and neck muscles on Day 1 followed by a second treatment at Week 12.
Trial: NCT00991796
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin concentrate for solution for infusion. once every 3 weeks for a maximum of 6 cycles. 6 mg/m2
Trial: NCT01055834
Drug: Eszopiclone 3 mg
RxNorm normalized name: eszopiclone 3 MG
DrugBank: Eszopiclone (DB00402)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group A Period I, Group B Period II:~Eszopiclone 3 mg tablet taken orally (po) with water as a single administration in the morning after fasting \>=10 hours.~Except for the water taken with the drug, participants were not allowed any food/ drink from 10 hours before until 4 hours after administration of drug. Except for the water taken with the study drug, participants were not permitted to drink water from 1 hour before until 1 hour after administration of drug.~Group B Period III:~Eszopiclone 3 mg tablet taken po with water as a single administration in the morning 30 minutes after the start of breakfast.~Except for the food/ drink at breakfast and the water taken with the study drug, participants were not allowed any food or drink from 10 hours before until 4 hours after administration of the drug. Except for the food/ drink at breakfast \& the water taken with the study drug, participants were not permitted to drink water from 1 hour before until 1 hour after administration.
Trial: NCT01055834
Drug: Eszopiclone 1 mg
RxNorm normalized name: eszopiclone 1 MG
DrugBank: Eszopiclone (DB00402)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group A Period II, Group B Period I:~Eszopiclone three 1 mg tablets (total: 3 mg) taken orally with water as a single administration in the morning after fasting 10 or more hours.~Except for the water taken with the study drug, participants were not allowed any food or drink (except water) from 10 hours before until 4 hours after administration of the study drug. Except for the water taken with the study drug, participants were not permitted to drink water from 1 hour before until 1 hour after administration of the study drug.
Trial: NCT02754219
Drug: Evogliptin
RxNorm normalized name: Evogliptin
DrugBank: Evogliptin (DB12625)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPP4-inhibitor, Evogliptin
Trial: NCT00684307
Drug: Vitamin-K antagonist at INR 2-3
RxNorm normalized name: Vitamin K 3
DrugBank: Menadione (DB00170)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet, PO for a period of 3-9 months.
Trial: NCT00275184
Drug: Senna
RxNorm normalized name: Senna
DrugBank: Senna leaf (DB15889)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00981838
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab (375 mg/m2) will be given as a single intravenous infusion after reconstitution in normal saline to a concentration of 1 mg/ml given though a 0.22 micron in line filter. The initial infusion rate will be 1 ml/kg/h and will be progressively increased up to 4 ml/kg/h according to drug tolerability. Pre-medication with steroids and/or antihistaminic agents will be done according to per-center's practice.Rituximab administration will be repeated in those patients \> 5 B cells/mm3 in the peripheral blood on the day after first Rituximab administration.
Trial: NCT01174849
Drug: Synflorix
DrugBank: Streptococcus pneumoniae type 1 capsular polysaccharide antigen (DB10319)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The 10-valent vaccine contains 1 µg of purified capsular polysaccharide of pneumococcal serotypes 1, 5, 6B, 7F, 9V, 14, and 23F conjugated to protein D, 3 µg of serotype 4 conjugated to protein D, 3 µg of serotype 18C conjugated to tetanus toxoid and 3 µg of serotype 19F conjugated to diphtheria toxoid.
Trial: NCT00275184
Drug: Metoclopramide
RxNorm normalized name: Metoclopramide
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02728050
Drug: Cladribine
RxNorm normalized name: Cladribine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV